S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in

Ra Medical Systems Stock Forecast, Price & News

+0.30 (+4.17 %)
(As of 01/21/2021 12:00 AM ET)
Today's Range
Now: $7.50
50-Day Range
MA: $7.03
52-Week Range
Now: $7.50
Volume351,217 shs
Average Volume241,948 shs
Market Capitalization$21.89 million
P/E RatioN/A
Dividend YieldN/A
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was founded in 2002 and is headquartered in Carlsbad, California.


Overall MarketRank

1.64 out of 5 stars

Medical Sector

271st out of 1,926 stocks

Surgical & Medical Instruments Industry

29th out of 169 stocks

Analyst Opinion: 3.2Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments



Sales & Book Value

Annual Sales$7.20 million
Book Value$61.81 per share


Net Income$-56,960,000.00
Net Margins-772.04%


Market Cap$21.89 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
+0.30 (+4.17 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RMED News and Ratings via Email

Sign-up to receive the latest news and ratings for RMED and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ra Medical Systems (NYSE:RMED) Frequently Asked Questions

How has Ra Medical Systems' stock been impacted by Coronavirus (COVID-19)?

Ra Medical Systems' stock was trading at $31.4075 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RMED stock has decreased by 76.1% and is now trading at $7.50.
View which stocks have been most impacted by COVID-19

Is Ra Medical Systems a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ra Medical Systems in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Ra Medical Systems stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMED, but not buy additional shares or sell existing shares.
View analyst ratings for Ra Medical Systems
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Ra Medical Systems?

Wall Street analysts have given Ra Medical Systems a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ra Medical Systems wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Larry J. Merlo's approval rating as Ra Medical Systems' CEO?

6,978 employees have rated Ra Medical Systems CEO Larry J. Merlo on Glassdoor.com. Larry J. Merlo has an approval rating of 37% among Ra Medical Systems' employees. This puts Larry J. Merlo in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Ra Medical Systems' next earnings date?

Ra Medical Systems is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Ra Medical Systems

How were Ra Medical Systems' earnings last quarter?

Ra Medical Systems, Inc. (NYSE:RMED) posted its earnings results on Thursday, November, 12th. The company reported ($3.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($3.00) by $0.25. The company had revenue of $0.91 million for the quarter, compared to analyst estimates of $1.13 million. Ra Medical Systems had a negative return on equity of 120.68% and a negative net margin of 772.04%.
View Ra Medical Systems' earnings history

When did Ra Medical Systems' stock split? How did Ra Medical Systems' stock split work?

Shares of Ra Medical Systems reverse split on Tuesday, November 17th 2020. The 1-25 reverse split was announced on Monday, November 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 16th 2020. An investor that had 100 shares of Ra Medical Systems stock prior to the reverse split would have 4 shares after the split.

What price target have analysts set for RMED?

3 Wall Street analysts have issued twelve-month price objectives for Ra Medical Systems' shares. Their forecasts range from $7.00 to $50.00. On average, they expect Ra Medical Systems' stock price to reach $31.50 in the next year. This suggests a possible upside of 320.0% from the stock's current price.
View analysts' price targets for Ra Medical Systems
or view Wall Street analyst' top-rated stocks.

Are investors shorting Ra Medical Systems?

Ra Medical Systems saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 76,200 shares, an increase of 32.1% from the December 15th total of 57,700 shares. Based on an average daily trading volume, of 255,600 shares, the days-to-cover ratio is currently 0.3 days. Currently, 2.9% of the company's stock are sold short.
View Ra Medical Systems' Short Interest

Who are some of Ra Medical Systems' key competitors?

What other stocks do shareholders of Ra Medical Systems own?

Who are Ra Medical Systems' key executives?

Ra Medical Systems' management team includes the following people:
  • Mr. Jeffrey Jay Kraws, Pres (Age 57, Pay $423.69k)
  • Mr. Andrew C. Jackson, Chief Financial Officer (Age 52, Pay $596.19k)
  • Mr. Daniel Horwood, Gen. Counsel & Sec. (Age 47, Pay $416.25k)
  • Mr. Jonathan Will McGuire, CEO & Director (Age 58)
  • Tiah Reppas, Chief Accounting Officer & Corp. Controller

When did Ra Medical Systems IPO?

(RMED) raised $50 million in an initial public offering on Thursday, September 27th 2018. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and Cantor acted as the underwriters for the IPO and SunTrust Robinson Humphrey, Nomura and Maxim Group were co-managers.

What is Ra Medical Systems' stock symbol?

Ra Medical Systems trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMED."

How do I buy shares of Ra Medical Systems?

Shares of RMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ra Medical Systems' stock price today?

One share of RMED stock can currently be purchased for approximately $7.50.

How big of a company is Ra Medical Systems?

Ra Medical Systems has a market capitalization of $21.89 million and generates $7.20 million in revenue each year. The company earns $-56,960,000.00 in net income (profit) each year or ($108.25) on an earnings per share basis. Ra Medical Systems employs 85 workers across the globe.

What is Ra Medical Systems' official website?

The official website for Ra Medical Systems is www.ramed.com.

How can I contact Ra Medical Systems?

Ra Medical Systems' mailing address is 2070 Las Palmas Drive, Carlsbad CA, 92011. The company can be reached via phone at 760-804-1648 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.